PSA Screening May Modestly Curb Prostate Cancer Deaths

Published Date: 16 Jun 2026

New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

Read Full News

Latest News

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

FDA Approves Iberdomide Combo for Multiple Myeloma

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

Wide Variation Seen in Lung Screening False-Positive Rates

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

Do High-Risk Features of Prostate Cancer Boost HT Benefit?

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

Todays Updates

NPM1-Mutated AML: Not All Treatments Are Equal

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

Todays Updates

NPM1-Mutated AML: Not All Treatments Are Equal

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

Latest News

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

News All Time

Breast Density Laws Fall Short Raising Additional Screening

State mandates requiring insurance coverage for additional breast cancer scans for those with dense breasts are failing to boost usage.

Is Shorter Radiation Linked to Lymphedema in Breast Cancer?

A trial tests whether 40Gy in 15 fractions over 3 weeks leads to more arm lymphedema than 50Gy in 25 fractions over 5 weeks.

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Despite Medicare Coverage, Cancer Genomic Testing Still Low

Medicare coverage of next-generation sequencing may have spurred an increase in the number of patients receiving genomic tests. But uptake remains low.

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Transperineal Biopsy IDs Active Surveillance Candidates

Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.

The Clues Hidden in Failed Prostate Cancer Trials

Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.

Palliative Care Remains Uncommon in Young Adults With Cancer

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.

Stem Cell Transplant Associated With Better PFS in NKTCL

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events

A lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.

Smoldering Myeloma: The Treatment Issue Is Getting Trickier

An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Patients With Early-Onset Cancer Unaware of Infertility Risk

Many patients with early-onset cancer say they were never told that treatments could affect their fertility.

Recommended News For You

Preventable pediatric cancer mortality surges in areas of armed conflict, exceeding rates in non-conflict regions

Indoor hydroponic gardening can improve mental health and quality of life for cancer patients

BTK Inhibitor Active in Half of Patients With Richter Transformation

Enhanced CAR T cell therapy offers new strategy for lymphoma

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

Because of the Medicare mail-order drug rule, oncologists run the risk of self-referral violations.

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Recommended Articles For You

Case-Based Learning on Adaptive Sequencing of Multimodal Therapy in Rare Solid Malignancies 

Unveiling the Invisible: The Transformative Role of Radiomics in Precision Oncology 

Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology 

Understanding Evans Syndrome: Causes, Symptoms, and Treatment Options  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

What is a "cancer vaccine" and is it the same as a COVID vaccine?

2.

ASCO Future Focus: Early Breast Cancer: Future Focus from the American Society of Clinical Oncology

3.

Clinical trial is testing whether heavy lifting could combat cancer side effects

4.

Booze and Pancreatic Cancer Risk; From 'Hospice' to 'Hope'; Gen Z-ers Skip Screening

5.

Relationship-building key to addressing oncologist shortages in rural care

1.

Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology

2.

Functional Iron Reserve Screening Before Clinical Deficiency: Clinical Insights and Evidence-Based Strategies

3.

Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors

4.

Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications

5.

What Is Gastrinoma? Understanding This Rare Tumor and Its Treatment Options

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

1.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

2.

Early Cancer Detection Saves Lives

3.

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III

5.

Navigating the Complexities of Ph Negative ALL - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot